Thermo Fisher Scientific CD264 (TRAIL-R4) Polyclonal Antibody

Applications

Tested Dilution

Publications

Immunocytochemistry (ICC/IF)

0.25-2 µg/mL

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Recombinant protein corresponding to Human TNFRSF10D. Recombinant protein control fragment (Product #RP-107784). if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:TRAIL-R4 (CD264),uniProtId:Q9UBN6-1,ncbiNodeId:9606,antigenRange:331-362,antigenLength:386,antigenImageFileName:PA5-84853_TRAIL-R4_CD264_Q9UBN6-1_Rabbit.svg,antigenImageFileNamePDP:PA5-84853_TRAIL-R4_CD264_Q9UBN6-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.05 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS, pH 7.2, with 40% glycerol

Contains

0.02% sodium azide

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Shipping conditions

Wet ice

RRID

AB_2792002

Product Specific Information

Immunogen sequence: LLVPVNDADS ADISTLLDAS ATLEEGHAKE TI

Target Information

TRAIL (also known as Apo-2L) is a member of the tumor necrosis factor (TNF) ligand family that rapidly induces apoptosis in a variety of transformed cell lines. A fourth member of the emerging TRAIL receptor family, TRAIL-R4, has signaling capacity similar to that of TRAIL-R1 and TRAIL-R2 with respect to NF-kappaB activation, but differs in its inability to induce apoptosis. Like TRAIL-R1 and TRAIL-R2, this receptor shows widespread tissue expression. The human TRAIL-R4 gene has been mapped to chromosome 8p22-21, clustered with three other TRAIL receptors.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.